Physician profile
Sameer A Azhak
NPI 1073672085
$3,827.76
in general payments reported to CMS, 2019-2025
35 companies · $616 in 2025
The $616 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $493 · 2021: $911 · 2022: $741 · 2023: $340 · 2024: $536 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $495.20 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $376.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.96 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $291.70 | 2019-2023 | Xarelto |
| Medtronic, INC. | $247.67 | 2021-2022 | |
| Pfizer INC. | $244.50 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $193.24 | 2019-2024 | |
| Abbott Laboratories | $158.84 | 2025 | Mitraclip |
| Boston Scientific Corporation | $132.23 | 2021-2024 | Watchman Access System, Watchman Flx, Watchman |
| E.R. Squibb & Sons, L.L.C. | $131.59 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $129.85 | 2022 | |
| Cvrx, INC. | $114.41 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals Lp | $101.83 | 2020-2024 | |
| Baxter Healthcare | $93.58 | 2024-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $73.47 | 2020-2024 | Nexletol |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $72.72 | 2024-2025 | Amvuttra |
| Bridgebio Pharma, INC. | $70.67 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.90 | 2019-2024 | Lifevest |
| Janssen Scientific Affairs, LLC | $68.37 | 2022 | |
| Amarin Pharma, INC. | $57.16 | 2020-2021 | |
| Lundbeck LLC | $54.00 | 2019-2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $40.82 | 2022-2023 | Arcalyst |
| Novo Nordisk INC | $39.76 | 2024-2025 | Wegovy |
| Impulse Dynamics (USA) INC. | $34.45 | 2022-2023 | Optimizer |
| Heartflow, INC. | $30.08 | 2023 | Ffrct |
| Arbor Pharmaceuticals, INC. | $28.05 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $27.96 | 2024 | Assure Wcd |
| Merck Sharp & Dohme LLC | $24.74 | 2021 | |
| Irhythm Technologies, INC. | $19.68 | 2022 | |
| Ionis Pharmaceuticals, INC. | $18.51 | 2025 | Tryngolza |
| Biotronik INC. | $17.40 | 2020 | |
| Daiichi Sankyo INC. | $14.87 | 2021 | |
| Acarix USA INC. | $14.56 | 2023 | Cadscor System |
| Otsuka America Pharmaceutical, INC. | $13.50 | 2019 | |
| G Medical Diagnostic Services, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Azhak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.